anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic abnormal uterine bleeding (AUB), involving menstrual bleeding of abnormal quantity, duration, frequency, or regularity is experienced by 10-50% of women of reproductive age, adversely impacts quality of life, and can have substantial adverse economic impacts on patients, and healthcare systems. One of the AUB symptoms, heavy menstrual bleeding (HMB), can lead to iron deficiency and iron deficiency anemia and in acute and severe cases, can necessitate emergency medical care. This study's focus is on the symptom of HMB which has a number of benign causes.

While pharmacologic treatment options exist, they are not always effective, and they are frequently associated with both side effects and ongoing cost of care. Consequently, some women desire more definitive options. Endometrial ablation (EA) is a minimally invasive approach designed to manage a number of the causes of HMB and can be performed under direct intrauterine vision with resectoscopic instruments or with a non-resectoscopic approach (non-resectoscopic endometrial ablation or NREA). For NREA, one of a number of specially designed device is inserted into the endometrial cavity to deliver thermal, cryogenic or radiofrequency electrical energy in an attempt to destroy the uterine lining or endometrium. In some jurisdictions, NREA has become an accepted office-based procedure, but is still usually performed in an institutional setting, is associated with risks associated with the procedure, anesthesia, and subsequent infertility, and has a failure rate that averages about 26%. These devices are typically expensive and require training for the surgeon and the ancillary support staff.

The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB. The suggested procedure is expected to be simpler than the currently available EA methods and yet should still reduce the need for a hysterectomy. This study will evaluate an additional exploratory endpoint in order to evaluate if there are detectable levels of silver in blood following SEAD treatment. SEAD treatment is performed locally by intrauterine administration for a duration of 30 minutes, during which the silver nitrate beads gradually dissolve. Upon dissolution the silver ions act on the mucus layer of the endometrium by binding to proteins and causing their denaturation, resulting in the formation of an eschar. The effect is local, and the bound silver is no longer active therefore it is unlikely that 100% of the silver dose will be available for absorption.
PROBLEM TO BE SOLVED: To prepare a manicure material excellent in such a viewpoint as easiness to be applied, extensibility in applying, etc., a feeling in using and scarceness in change with time, by including composite powder comprising poly (organosiloxane). SOLUTION: This manicure material is prepared by including (pref. 0. 01-20 wt.%) composite powder comprising various kinds of poly(organosiloxane). It is pref. that the composite powder is prepared by the following steps: (1) adding a catalyst to an oil-based 0/W emulsion containing (i) a vinyl group- containing poly(organosiloxane) and (ii) a poly organohydrogensiloxane to cause curing reaction and to produce aqueous dispersion of the finely divided particle of spherical silicone rubber cured product; (2) adding an alkaline substance or an alkaline aqueous solution, and organotrialkoxysilane to the dispersion so as to cause hydrolysis and condensation curing reaction and then drying, and is finely divided particle with an average particle diameter of 0.1-100 μm of spherical silicone rubber cured product covered with poly organosilsesquioxane.
Subjects will randomly receive either dexamethasone or placebo and begin the study medication during the midpoint of their radiation treatment. Study medication will be taken for 14 straight days then stopped. Fatigue and quality of life will be measured weekly with short patient completed surveys. The number of breaks taken during radiation treatment will also be tracked. For safety, blood sugar levels will be checked with finger stick blood draws because dexamethasone is known to cause these levels to increase. Study participation will be approximately 3 months.
At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the intervention group and will be prescribed compression stockings and individualized exercise. They will also receive standard education on lymphedema risk reduction.
We investigated whether linoleic acid (LA) supplementation could modulate emotional behavior and microglia-related neuroinflammation. For that, male mice of C57BL/6J genetic background fed either a high-fat diet (HFD) or a standard diet (STD) for 12 weeks, were treated with a vehicle or LA solution for 5 weeks before being evaluated for emotional behavior using a battery of behavioral tests. The animals were subsequently sacrificed and their brains collected and processed for immunofluorescence staining, targeting microglia-specific calcium-binding proteins (IBA-1). Neuroinflammation severity was assessed in multiple hypothalamic, cortical and subcortical brain regions. We show an anxio-depressive-like effect of sustained HFD feeding that was neither alleviated nor worsened with LA supplementation. However, increased IBA-1 expression and microgliosis in the HFD group were largely attenuated by LA supplementation. These observations demonstrate that the anti-neuroinflammatory properties of LA are not restricted to hypothalamic areas but are also evident at the cortical and subcortical levels. This study discloses that neuroinflammation plays a role in the genesis of neuropsychiatric disorders in the context of obesity, and that LA supplementation is a useful dietary strategy to alleviate the impact of obesity-related neuroinflammation.
1062 children at the age of 7 months and their families were randomized 1:1 in an intervention arm and a control arm. The intervention families has received child-oriented and individualized nutritional and life-style counseling that aims at decreasing child's exposure to the known environmental atherosclerosis risk factors. The controls children receive information as given at the well-baby clinics and in school health care of children and adolescents. The hypothesis is that the intervention children have healthier food habits and serum serum lipid and lipoprotein concentrations than the controls, fewer of them start smoking, and their physical activity level is higher than that of the controls. We further hypothesised that the life-style intervention had no adverse mental or somatic effects on the children. Intima-media thickness of the carotid and brachial arterias and aorta and vasodilatation of the brachial artery induced by endogenous NO production have been also been measures at 2-year intervals since the age of 11 years. Recruitment to the study began in 1990 and continued for 2 years. The children are now between 14 and 16 years of age. 550 children remain in the study, which will continue until the last children have reached the age of 20 years.
1/ Dietetic applications A release of the micronutrients at the appropriate point in the digestive tract is brought about by the technique of coacervation in gelatin followed by crosslinking. This results in:     - increased tolerance,   - lack of competition between micronutrients,   - protection of the micronutrients against gastric acidity,   - intact bioavailability,   - sequential absorption of the micronutrients.   2/ Pharmaceutical applications The invention enables therapeutic active principles previously chelated around a metal to be protected, transported and released at will. When performed in the absence of oxygen, the method makes it possible to bring about a better balance of the intestinal flora using strict anaerobic ferments. It permits the simultaneous administration of water-soluble and fat-soluble medicaments. Depending on the degree of crosslinking of the gelatin and the nature of the coatings carried out, the invention enables the release of the active principles to be staggered over time. This is the meaning of the term "differential timed release".
This is an adaptive open label Phase 2a study to examine the antimalarial efficacy, safety, and tolerability of SJ733 in adult patients with uncomplicated P. vivax or P. falciparum blood-stage malaria monoinfection. SJ733 will be administered orally once every day for three consecutive days, with or without a fixed dose of the pharmacoenhancer cobicistat. The Phase 1 clinical data (completed under a US IND) and PK/PD models suggest that SJ733 is most likely to be curative as a 3-daily-dose pharmacoenhanced therapy, due to its moderately rapid clearance. There will be 1-3 cohorts with each cohort containing two treatment arms, P. falciparum (a) and P. vivax (b). Cohort progression will be managed independently for each treatment arm. Interim analysis will determine whether the data for a given treatment arm meets the success criteria, is inconclusive, or meets the failure criteria. Antimalarial efficacy will be examined over the period of 42 days. Additional aims are to characterize the safety and pharmacokinetics of SJ733. The results of this trial will identify active, well-tolerated doses for investigation in a larger Phase 2b clinical trial.
Elective Cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. The operation will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
PURPOSE: To obtain a useful composition in a field except reconstruction and transplantation of a texture and also useful in the field of cosmetic surgery, by forming a collagen flake constructing an uneven channel of a collagem fiber connecting a surface to an inner part, and by providing a collagen flake with a hole for mutual connection. CONSTITUTION: A collagen fiber whose configuration of flake forms a web like mesh has a net structure, and shows a manifold of collagen fibers forming a sheet structure with channels among respective collagen fibers and between sheets of collagen fiber. The channel connects surface fine hole to a fine hole in a sponge. The collagen fiber has fine holes, most of which connect mutually and of which considerable parts connect to the channel. As the flake is composed of the collagen fiber, its strength is equal to the fiber. The flake absorbs not only liquid matter from an edema but also bacteria in an incision.
Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5.2)]. 

For relief of the pain of osteoarthritis (OA) of the knee(s), the recommended dose is 40 mg of diclofenac sodium (2 pump actuations) on each painful knee, 2 times a day. 

Apply diclofenac sodium topical solution to clean, dry skin. 

The pump must be primed before first use. Instruct patients to fully depress the pump mechanism (actuation) 4 times while holding the bottle in an upright position. This portion should be discarded to ensure proper priming of the pump. No further priming of the bottle should be required. 

After the priming procedure, diclofenac sodium topical solution is properly dispensed by completely depressing the pump 2 times to achieve the prescribed dosage for one knee. Deliver the product directly into the palm of the hand and then apply evenly around front, back, and sides of the knee. 

Application of diclofenac sodium topical solution in an amount exceeding or less than the recommended dose has not been studied and is therefore not recommended.
Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
PURPOSE:To obtain a vital energetic cosmetic having sufficient effects (the effects on the improvement in physical strength and physiological function of the skin, beautifying of the face, conditioning of the skin, etc.) by generating strong vital energy so as to exceed KIKO-ISHI (a vital energizing physician according to a Chinese therapy) with a machine and subjecting a cosmetic to irradiation treatment therewith. CONSTITUTION:This cosmetic is obtained by irradiation with the wave motion SEIOC or SEIMM generated from a device according to the invention (1) patent application No. 4-322616 or (2) patent application (applied on December 19, 1992) accomplished by this inventor. Water, a cosmetic, a chemical, a soft drink, cooked rice, paper, etc., are irradiated with the wave motion of the SEIOC or SEIMM and the vital energy of the human body can be reinforced by drinking the irradiated water, etc., or applying the irradiated cosmetic, etc., to the skin. Thereby, actions such as recovery of physical strength and improvement in physiological function of the skin produced in receiving the external vial energy irradiation by a vital energizing physician according to a Chinese therapy appear.
Atherosclerosis, a lipid-driven chronic inflammatory disorder, is a significant global health concern associated with high rates of morbidity and mortality, imposing a substantial societal burden. The purpose of this study is to investigate the possible molecular mechanisms of atherosclerosis and identify potential therapeutic targets. We conducted an integrated bioinformatics analysis using data from peripheral blood mononuclear cell and TISSUE databases obtained from the Gene Expression Omnibus, to identify key genes associated with the progression of atherosclerosis. Here, IRF8 was found to be a key gene in atherosclerosis patients. Silencing IRF8 with small interfering RNA reduced inflammation in endothelial cells. This suggests IRF8 is a crucial biomarker for immune infiltration in atherosclerosis advance.
Each subject after consent will undergo a biopsy of one cutaneous neurofibroma prior to treatment. The participant will then undergo a sensitization treatment to "normal" skin as well as one neurofibroma to activate the immune system against the trial drug. 14 days after sensitization, patients will begin the first of 10 weekly treatment doses to a minimum of 3, up to 20 cutaneous neurofibromas. The participant may require up to 2 additional sensitization exposures. When the investigator has determined that sensitization has occurred, each subject will have a skin biopsy of one treated neurofibroma 3 days after initial treatment on Day 17 in order to investigate cellular and molecular effects of the treatment. The remainder of treatments will be applied once weekly on days 21, 28, 35, 42, 49, 56, 63, 70, and 77. The followup visit will occur on Day 107. Tumors will be photographed at screening and at each treatment visit, and in addition, whole body photography will be performed on Day 0 and Day 107 to assess for off-target effects on cutaneous neurofibromas that were not directly treated. On Day 107, a third cutaneous neurofibroma will be biopsied for molecular and immunohistopathological outcomes.
Healthy volunteers are informed that a new application method for a well-known antidepressant would be tested. They will randomly be assigned to the experimental group (taking the antidepressant which is in fact an active placebo) or the control group (not taking a placebo). Then participants watch a well established film sequence to induce sadness. Sadness is assessed before and after receiving the nasal spray and watching the film sequence. In the seven consecutive days the participant's mood is assessed each day, only the experimental group is taking the placebo each day. Afterwards participants will watch another sad film sequence and sadness will be assessed before and afterwards.
Participants will receive a single session intervention of behavioral activation (BA) psychotherapy. Stimulation will be delivered via the NeuroConn DC-STIMULATOR MC at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. The tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
The present invention discloses the use of a composition comprising an effective amount of an extract of Eurycoma longifolia for the production of a preparation to stimulate and/or enhance the immune system. In a preferred embodiment, the extract comprises active ingredients, which include eurycomanone, protein, polysaccharide and glycosaponin in appropriate amounts. In, another preferred embodiment, the extract has an activity selected from the group consisting of: * increasing the number of T-ceils; * improving Scoring of Immunological Vigor (SIV), a comprehensive index of overall immune function; * lowering the immunological age, a comprehensible form of immune function based on T-celi number and proliferative activity; * reducing fatigue; and * alleviating or reducing stress. Also disclosed is a method of for treating an individual to achieve an outcome selected from the group consisting of increasing the number of T-celis, improving SIV (i.e. a comprehensive index of overall immune function), lowering the immunological age (i.e. a comprehensible form of immune function), reducing fatigue and alleviating or reducing stress comprising administering to the individual an effective amount of an extract of Eurycoma longifolia.
Cataract formation is a natural aging process that can be influenced by environmental factors such as exposure to ultra violet light and diet. Additionally, metabolic disorders, such as diabetes can lead to an earlier development of cataracts. As cataracts develop, a patient's vision can be affected. Reduced vision can limit activities of daily living and may even reduce a patient's mobility. When this occurs, cataract surgery should be considered to help restore a patient's vision. With the obesity and diabetic epidemic, proper diet and exercise is a major health initiative to control these diseases. If a patient's mobility is reduced as a result of poor vision - their ability to achieve adequate daily physical activity may also be effected. It is thought that improvement in vision may increase their activity levels and help combat these health issues. This study will investigate the activity level of patients before and after undergoing cataract surgery to determine how improved vision quality from removal of the natural lens inside the eye and replacement with an artificial intraocular lens effects their activity level.
PURPOSE: To obtain an X-ray contrast medium pharmaceuticals which contain an alkyl ether of triiodophenol as an X-ray contrast medium, are so prepd. as to hold this alkyl ether in an aq. dispersion form in a compsn. and may be orally or rectally dosed for X-ray inspection of the gastrointestinal tracts. CONSTITUTION: This compsn. in the aq. suspension form contains the X-ray contrast medium of formula I (R is a 3 to 8C substd. or unsubstd. alkyl; (n) is 1 to 5) (more particularly, the compd. of formula II is adequate) and is usable for radiodiagnosis of the gastrointestinal tracts. While the compsn. is a dispersion, colloid or suspension form, the suspension is more preferable. Surfactants are recommended to be incorporated into the dispersion. the examples thereof are cationic surfactants, such as cetyltrimethyl ammonium bromide, anionic surfactants, such as sodium lauryl sulfate, and nonionic surfactants, such as carboxylates. Any of a suspending agent, stabilizing agent, antioxidant, osmole concn. control agent, buffering agent, pH control agent, flavor, etc., may further be added to such compsn.
VIA, which is standard of care for cervical cancer screening in Zambia, will be carried out using the methodology described by IARC. This is summarized as follows: visualization of the vagina, vulva and cervix following insertion of a speculum; assessment with the naked eye after application of normal saline; and further assessment after application of 5% acetic acid for 1 minute. This will be recorded as normal or abnormal by the assessor.
PURPOSE: Functional endoscopic sinus surgery (FESS) is a mainstay surgical intervention for chronic rhinosinusitis with nasal polyposis (CRSwNP). Nasal irrigation, particularly with normal saline, is a widely recommended postoperative care modality. This systematic review and meta-analysis aimed to assess the efficacy of various nasal irrigation solutions in postoperative FESS patients.
METHODS: A comprehensive search was conducted in multiple databases for randomized controlled trials investigating normal saline and various substances for nasal irrigation post-FESS. The systematic review followed PRISMA guidelines, and the meta-analysis used R software for data synthesis. Outcome measures included SNOT-22 and LKES scores. The Cochrane tool was employed to evaluate the potential for bias.
RESULTS: Results from 14 studies, focusing on six each for SNOT-22 and LKES, revealed a significant reduction in symptoms and endoscopic scores with various solutions compared to normal saline. The meta-analysis using the random-effects model indicated a negative standardized mean difference (SMD) of - 0.69(95% CI [- 1.64; 0.27], p = 0.157) for symptoms and endoscopic scores (SMD = - 0.48, 95% CI [- 1.32; 0.36], z = - 1.12, p = 0.264). Subgroup analyses highlighted budesonide's efficacy over normal saline, but substantial heterogeneity and potential publication bias were noted.
CONCLUSION: Nasal irrigation with various solutions postoperative FESS patients demonstrated significant improvements in patient-reported symptoms and endoscopic scores compared to normal saline. Budesonide appeared particularly effective. However, high heterogeneity and potential publication bias warrant cautious interpretation. Standardized outcome measures and further research are needed to strengthen the evidence.
Drug intervention: Lapatinib IMP, Trastuzumab on prescription. Lapatinib 1000 mg p.o. once daily for 21 days. Trastuzumab i.v. infusion 8 mg/kg loading dose; 6 mg/kg on Day 1 of each subsequent 3 weekly cycle.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of hiding the bitterness of a composition by a simple composition using a stable additive, having an excellent feeling in administration, capable of rapidly dissolving a medicine in digestive tracts, not reducing biological availability, by adding a nonionic surfactant to a medicine having bitterness. SOLUTION: This composition is obtained by adding (B) a nonionic surfactant such as preferably a propylene glycol fatty acid ester, a sorbitan fatty acid ester, etc., to (A) a medicine having bitterness such as quinine hydrochloride, theophylline, etc., in the ratio of preferably 0.01-100 pts.wt., more preferably 0.1-20 pts.wt. of the component B to 1 pt.wt. of the component A. In the composition, preferably the component A and the component B form a complex by a hydrophobic interaction in an aqueous solution and/or oral cavity. The composition is provided as a solid preparation.
A cookie that provides a prebiotic effect and/or a probiotic effect to a consumer is described. The cookie fails to contain refined sugars, synthetic vitamins, genetically modified organisms (GMOs), artificial sweeteners, and artificial preservatives. The cookie comprises at least two baked food compositions formed into a biscuit. Each of the at least two baked food compositions contains a polyphenol, a resistant starch, and a prebiotic soluble fiber. A crème filing is sandwiched between the at least two baked food compositions. The crème filing comprises a resistant starch, a nut butter, a vegetable fat, and spores of a probiotic bacterium. Consumption of the cookie increases Lactobacillus bulgaricus and butyrate in the consumer.